Equities Analysts Issue Forecasts for PVLA FY2029 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Palvella Therapeutics in a report issued on Friday, January 3rd. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.69) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald began coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $13.25 on Monday. The firm has a market cap of $17.49 million, a PE ratio of -1.10 and a beta of 0.61. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.39% of the stock is owned by corporate insiders.